TriangleSBRT + atezolizumab and bevacizumab (NCT05488522)
SBRT + atezolizumab and bevacizumab trial for Unresectable Hepatocellular Carcinoma (NCT05488522). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for advanced hepatocellular carcinoma, a liver cancer, that cannot be treated with curative surgery or ablation and needs systemic therapy, in adults.
The idea: repeat radiation alongside immunotherapy. Stereotactic body radiotherapy is given in repeated doses together with atezolizumab and bevacizumab. Both drugs are FDA approved for advanced liver cancer in combination.
This phase 1 study raises the radiation dose in steps to find a safe dose, and plans 18 patients. At the Abramson Cancer Center at Penn Medicine in Philadelphia, Edgar Ben-Josef leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.